GLP weight-loss drug Ozempic has reportedly been linked to a rare form of vision loss, known as non-arteritic anterior ischemic optic neuropathy (NAION). The study, which has yet to be peer-reviewed, ...
For the first time in a decade, obesity in the U.S. is declining — and a new study suggests it’s because of wildly popular medications such as Ozempic.
Obesity dipped slightly in U.S. adults last year, research found — the first time in more than a decade that the country has ...
People taking Ozempic and Wegovy, which contain the drug semaglutide, may be at an increased risk of developing a ...
Novo Nordisk’s (NVO) blockbuster diabetes drug Ozempic may have a potential link with an eye condition that causes vision ...
Some people are not taking weight-loss medications responsibly, the physician says, and don't realize their full implications ...
Brownstein and his team noted that women and adults aged 66 to 75 saw the largest decreases in obesity. People living in the ...
NVO's CagriSema target of up to 25% in long-term weight loss is highly promising vs. 15% through Wegovy and 20% through ...
5h
Semaglutide use in diabetes patients is linked to a higher risk of NAION, a rare eye condition. A Danish-Norwegian study ...
Over half of American adults are eligible for semaglutide, but insurance and other barriers make it hard for people to access ...
Novo Nordisk’s (NVO) blockbuster diabetes drug Ozempic may have a potential link with an eye condition that causes vision ...
Popular GLP-1 medications like semaglutide in Ozempic and Wegovy help people lose weight, but what should patients know about ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback